Drug Profile
Alvimopan - Merck
Alternative Names: ADL 8-2698; ADL2698; Entereg; Entrareg; LY 246736Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Adolor Corporation; Merck & Co
- Class Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Postoperative ileus
- Discontinued Constipation; Irritable bowel syndrome
Most Recent Events
- 01 Jul 2015 Cubist Pharmaceuticals initiates enrolment in a phase II trial for Postoperative ileus in USA (NCT02379858)
- 18 Mar 2015 Cubist Pharmaceuticals plans a phase II trial for Postoperative ileus in USA (NCT02379858).
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co